Current Open Cancer Clinical Trials
Clinical Trials Currently Enrolling Subjects
Breast Cancer
Helping Ourselves, Helping Others: The Young Women’s Breast Cancer Study
Aim: Breast cancer is the most common malignancy in women in the United States. Young women are not underrepresented in clinical trials, but there are rarely a sufficient number of young women in any trial to draw meaningful conclusions about this subgroup.
Researchers at New England Hematology/Oncology and Dana-Farber Cancer Institute are collaborating on this study that examines breast cancer in young women. We are trying to learn more about how breast cancer in young women affects their lives. We are particularly interested in young women’s emotional well-being, fertility concerns, sexual functioning, and physical health and treatment decisions.
Lymphoma Associated with Breast Implants
Aim: Collaboratively investigators at MGH and NWH are interested in examining patients who have had breast implants and have developed lymphoma. The aim of the study is to assess historical lymphoma data and assess patient outcomes in the historical cases.
Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-paclitaxel, All Combined with Bevacizumab, as First-line Therapy for Locally Recurrent or Metastatic Breast Cancer
Aim: Researchers at New England Hematology/Oncology and Dana-Farber Cancer Institute are collaborating on this study that examines outcomes for treatment of breast cancer.
Randomized Phase III Trial Of Paclitaxel Combined With Trastuzumab, Lapatinib, Or Both As Neoadjuvant Treatment Of Her2-Positive Primary Breast Cancer
Aim: Researchers at New England Hematology/Oncology and Dana-Farber Cancer Institute are collaborating on this study that examines treatment given in addition to standard treatment for Her2 positive breast cancer.
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Aim: The purpose of this study is to determine the safety and tolerability of the combination of two drugs (letrozole and leuprolide) in women who have already taken tamoxifen for at least 4.5 years.
Breast and Ovarian Cancer
Genetic and Other Causes of Cancer. Risk Evaluation And Cancer History (REACH) Questionnaire. The REACH project collects risk factor information, blood and tissue specimens from patients and family members at high risk for breast and/or ovarian cancer. The data and specimen bank will be used as a resource to be shared with researchers working in the areas of breast and ovarian cancer risk, prevention and treatment.
Colon/Rectal Cancer
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Aim: Researchers at New England Hematology/Oncology and Dana-Farber Cancer Institute are collaborating on this study that examines treatment for colon and rectal cancer.
Observational Study
Observational Study of the Mechanisms of Hypertension and Proteinuria in Patients Treated with Anti-Angiogenic Chemotherapies.
Aim: Researchers at New England Hematology/Oncology and Dana-Farber Cancer Institute are collaborating on this observational study that examines blood pressure and cancer treatment.
|
